detected on Pap smearEVIDENCEBASED ANSWERespecially if the sample can be obtained at thesame time as the Papanicolaou Pap smear can brought to you by CORE View metadata citation and similar pap ID: 936609
Download Pdf The PPT/PDF document "MARCH 2004VOL 53 NO 34Benninger MS Anon ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
MARCH 2004/VOL 53, NO 34.Benninger MS, Anon J, Mabry RL. The medical management5.Clement PA, Bluestone CD, Gordts F, et al. Management of detected on Pap smear?EVIDENCE-BASED ANSWERespecially if the sample can be obtained at thesame time as the Papanicolaou (Pap) smear, can brought to you by CORE View metadata, citation and similar papers at core.ac.uk provided by University of Missouri: MOspace MARCH 2004/VOL 53, NO 3 CLINICALCOMMENTARY lenge to ensure that patients follow our recom-tion of HSIL. Best of all, fewer women areJohn Hill, MD,Center, Denver1.Manos MM, Kinney WK, Hurley LB, et al. Identifyingwomen with cervical neoplasia: using human papillo-2.Solomon D, Schiffman M, Tarone R; ALTS Study Group.3.Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alter-4.Schiffman M, Solomon D. Findings to date from the A
SCUS-LSILTriage Study (ALTS). 5.Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ;6.US Preventive Services Task Force. Screening for cervicalAgency for Healthcare Research and Quality. Available at:www.ahcpr.gov/clinic/uspstf/uspscerv.htm. Accessed onAre ARBs or ACE inhibitorspreferred for nephropathy in diabetes?EVIDENCE-BASED ANSWERinhibitors have not been as well studied for theendpoint of nephropathy, patients with nephropa-thy exhibit reduced mortality when treated withEVIDENCE SUMMARYÑa multicenter, randomized,(NNT) for the composite outcome was 34. The NNTuria) study,a multicenter, randomized, double-patients with type 2 diabetes, hypertension, andmg of irbesartan (Avapro) or placebo. Additionalwith the exception of ACE inhibitors, ARBs, anddihydropyridine calcium-channel blockers. The www.jfponline.com